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NCT03959748) is the  first multicenter and 
prospective registry of adult and pediatric pa‑
tients with PAH and CTEPH created in any 
of the Central ‑Eastern European countries. In 
the present report, we describe the design of 
the registry.
Objectives of the BNP ‑PL registry The BNP ‑PL 
registry is an initiative of the Working Group 
on Pulmonary Circulation of the Polish Cardi‑
ac Society in cooperation with Polish PH refer‑
ence centers6‑9 to assess prospectively the epi‑
demiology, clinical course, and disease manage‑
ment of patients with PAH and CTEPH. The spe‑
cific objectives of the study are shown in Sup‑
plementary material, Table S1.
Introduction Pulmonary arterial hyperten‑
sion (PAH) and chronic thromboembolic pul‑
monary hypertension (CTEPH) are rare types 
of pulmonary hypertension (PH). Consequently, 
patient registries are key instruments that pro‑
vide data for clinical research and improve pa‑
tient care and healthcare planning.1
Currently, most of our knowledge on PAH 
and CTEPH epidemiology, management, and 
treatment outcomes come from registries orig‑
inating in the Western populations.2‑5 However, 
a global view on the epidemiology of PH reveals 
important geographical differences.1
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of the  Jagiellonian University Medical Col‑
lege, which ensures system integrity and data 
protection.
Cohort size and study duration Enrollment to our 
study started on March 1, 2018 and is planned 
to continue at least until February 28, 2023. We 
plan to collect the follow ‑up data for a minimum 
of 5 years from the enrollment of the last patient. 
As our registry is mostly descriptive, the study 
size is not prespecified.
Prevalence and incidence The  prevalence of 
PAH and CTEPH will be calculated separate‑
ly for adults (≥18 years of age) and children 
( ≥3 months and <18 years of age) as the number 
of cases per 1 000 000 inhabitants, and the in‑
cidence, as the number of new cases of PAH or 
CTEPH per 1 000 000 inhabitants each year. Data 
for the number of adults and children living in 
Poland will be acquired from the publications of 
Statistics Poland (https://stat.gov.pl)
Baseline assessment In incident cases, the base‑
line assessment includes data acquired at the di‑
agnosis of PAH or CTEPH, including the first 
prescribed treatment (Supplementary materi‑
al, Table S2). We also collect information about 
the first symptoms and the time elapsed from 
the first symptoms to diagnosis. In prevalent 
cases, the baseline assessment includes data ob‑
tained at the most recent visit after March 1, 2018 
and also from the most recent right heart cath‑
eterization. We also record the date of diagno‑
sis and patient’s functional class at that time. 
The date of PAH or CTEPH diagnosis is defined 
as the date of the first right heart catheteriza‑
tion11 fulfilling the hemodynamic criteria for pre‑
capillary PH.
Follow ‑up assessment Follow ‑up data (Sup‑
plementary material, Table S3) will be record‑
ed in the database every year between Septem‑
ber 1 and October 30, starting in 2019. Accord‑
ingly, follow ‑up data will include the most recent 
information on patients’ status before Septem‑
ber 1 each year, including changes in treatment, 
major clinical events and outcomes, and results 
of additional tests performed in a patient in 
the last 12 months.
Treatment Medical therapy in patients with 
PAH and CTEPH in Poland is reimbursed by 
the NFZ in a structured program with specific 
inclusion and exclusion criteria. This program is 
subject to change along with new drug approvals.
Discussion Bias and generalizability of the re‑
sults Enrollment of both prevalent and incident 
patients may bias the outcome analysis as data 
on patients with prevalent cases who did not 
survive until the study enrollment will not be 
Methods Organization of the BNP ‑PL regis‑
try An invitation to participate in the study was 
sent to Polish centers (22 adult and 8 pediat‑
ric centers) that were accredited to treat PAH or 
CTEPH by the Polish National Health Fund (Nar‑
odowy Fundusz Zdrowia, NFZ), the only health‑
care payer in Poland. Of the invited centers, all of 
the adult and pediatric centers accepted the in‑
vitation and were formally involved in the proj‑
ect. Design of the registry is shown in FIGURE 1 and 
is further described in Supplementary materi‑
al, Methods S1.
The protocol of the study was reviewed and 
accepted by the Bioethical Committee of Physi‑
cians and Dentists Chamber in Kraków.
Participants Patients with PAH and CTEPH old‑
er than 3 months of age and treated in the par‑
ticipating centers are enrolled to the BNP ‑PL 
registry to form 4 separate arms as shown in 
FIGURE 1A. Patients with both newly and previous‑
ly diagnosed PAH or CTEPH are eligible. New‑
ly diagnosed is defined as diagnosis established 
after March 1, 2018 (termed “incident cases”). 
Patients who were diagnosed earlier are classi‑
fied as “prevalent cases” (FIGURE 1B). For the pur‑
pose of the study, we use the most recent defi‑
nitions of PAH and CTEPH as recommended by 
the European Society of Cardiology (Supplemen‑
tary material, Methods S2).10
Patient records are submitted by local coor‑
dinators to a dedicated internet platform cre‑
ated and managed by the Informatics Centre 
BNP-PL
PAH adults
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FIGURE 1 Design of the Database of Pulmonary Hypertension in the Polish Population 
(BNP ‑PL) registry: A – four arms of the BNP ‑PL registry including adults and children with 
pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension 
(CTEPH). Two additional arms of the CTEPH group represent patients treated with balloon 
pulmonary angioplasty (BPA) and pulmonary endarterectomy (PEA). B – time points of 
enrollment and follow ‑up of prevalent and incident cases
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B
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we have planned a long ‑term continuous enroll‑
ment of incident patients.
Conclusions The BNP ‑PL registry is designed 
to show the epidemiology and characteristics 
of PAH and CTEPH in a large Central ‑Eastern 
post ‑communist European country with a rel‑
atively short history of availability of modern 







CONFLICT OF INTEREST None declared.
OPEN ACCESS This  is  an Open  Access  article  distributed  under  the  terms 
of  the  Creative  Commons  Attribution ‑NonCommercial ‑NoDerivatives  4.0  In‑

















































recorded. Accordingly, we plan to perform sep‑
arate analysis in prevalent and incident groups. 
Additional bias may be related to the enrollment 
of patients participating in clinical trials since 
they may be receiving better care than others. 
However, exclusion of these patients would af‑
fect the real ‑life profile of our population.
Due to specific organization of treatment of 
patients with PAH and CTEPH in Poland in cen‑
ters accredited by the NFZ, we believe that we 
will enroll to enroll almost all affected individ‑
uals in our analysis. In that way, our results will 
be representative of the recently diagnosed pa‑
tients with PAH or CTEPH and of patients who 
lived with PAH or CTEPH long enough to be rep‑
resented in the registry. Still, our data will not 
be generalizable to patients with PAH or CTEPH 
who have not been yet diagnosed.
Comparison with other registries on pulmonary hy‑
pertension In their recent systematic literature 
search, Skride et al12 identified 11 prospective 
registries performed in patients with PH from 
Europe. Most of them were national (4 single‑
‑center and 6 multicenter registries) and only 1 
involved multiple international centers. Three 
registries involved all groups of patients with 
PH, while others were limited exclusively to pa‑
tients with PAH and CTEPH (3 studies), with 
PAH (2 studies), with IPAH (1 study), or with 
CTEPH (1 study).13 Six studies recruited only in‑
cident cases while the other 5 registries enrolled 
patients both with incident and prevalent cases. 
With 1 exception, the registries were performed 
in Western European countries, which shows 
that patients with PH from the Central ‑Eastern 
European countries have not been well repre‑
sented in the literature. In 1 single ‑center pro‑
spective study, 130 adult patients with PAH and 
44 with CTEPH were followed for a median of 33 
months to report the survival rates in the Lat‑
vian population.8 Another registry by Jansa et 
al14 was a retrospective analysis of 191 preva‑
lent and incident adult patients diagnosed with 
PAH in 2 specialized centers in Czech Republic.
The BNP ‑PL registry is the first multicenter, 
nationwide prospective registry compiled in 
a Central ‑Eastern European country to assess 
patients with PAH and CTEPH. The design of 
the BNP ‑PL registry has some similarities with 
the largest ever PAH registry (Registry to Eval‑
uate Early and Long ‑term PAH Disease Manage‑
ment; REVEAL) which was initiated in the Unit‑
ed States in 2006 to prospectively analyze char‑
acteristics of patients with PAH in the modern 
era of novel treatment options.1 Similarly to 
the REVEAL registry, our patients are recruit‑
ed from several pulmonary hypertension refer‑
ence centers and we include both adults and chil‑
dren as well as patients with prevalent and inci‑
dent diseases. In contrast to the REVEAL study, 
and similarly to the large European registries,3‑5 
